Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 10, 2015, Pages 589-604

  Eaton, Joshua Seth ^a   Miller, Paul E ^a,b   Mannis, Mark J ^c   Murphy, Christopher J ^a,c,d  

^a OSOD Ocular Services on Demand   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGS 16C3F AURISTATIN; AGS 16M8F AURISTATIN; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; AVE 9633; BT 062; CANTUZUMAB RAVTANSINE; CD3 ANTIBODY; COLTUXIMAB RAVTANSINE; DENINTUZUMAB MAFODOTIN; GEMTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MEDI 547; MIRVETUXIMAB SORAVTANSINE; SAR 566658; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VORSETUZUMAB MAFODOTIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; ASTIGMATISM; BLURRED VISION; BONE MARROW SUPPRESSION; CATARACT; CEREBRAL BLINDNESS; CLINICAL TRIAL (TOPIC); CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA DISEASE; DIPLOPIA; DISORIENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE IRRITATION; EYE PAIN; EYE REDNESS; EYE TOXICITY; HEADACHE; HUMAN; INTRAOCULAR HEMORRHAGE; KERATITIS; KERATOCONJUNCTIVITIS; KERATOPATHY; LACRIMAL GLAND DISEASE; LACRIMATION DISORDER; NAUSEA; NONHUMAN; OCULAR SURFACE DISEASE; OPTIC NERVE DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOPHOBIA; PIGMENT DISORDER; PUNCTATE KERATITIS; REFRACTION ERROR; RETINOPATHY; REVIEW; SCOTOMA; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UVEITIS; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG DESIGN; EYE DISEASE; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; EYE DISEASES; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84973295062     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2015.0064     Document Type: Review

References (112)

1. Scott, A.M., Wolchok, J.D., and Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer. 12:278-287, 2012
2. Oldham, R.K., and Dillman, R.O. Monoclonal antibodies in cancer therapy: 25 years of progress. J. Clin. Oncol. 26:1774-1777, 2008
3. Reichert, J. Therapeutic monoclonal antibodies approved or in review in the European Union or United States. http:// www.antibodysociety.org/news/approved-mabs.php; 2015. Last accessed August 20, 2015
4. Zigler, M., Shir, A., and Levitzki, A. Targeted cancer immunotherapy. Curr. Opin. Pharmacol. 13:504-510, 2013
5. Kheir, W.J., Sniegowski, M.C., El-Sawy, T., et al. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Surv. Ophthalmol. 59:493-502, 2014
6. Renouf, D.J., Velazquez-Martin, J.P., Simpson, R., et al. Ocular toxicity of targeted therapies. J. Clin. Oncol. 30: 3277-3286, 2012
7. Jusufbegovic, D., Triozzi, P.L., and Singh, A.D. Targeted therapy and their ocular complications. In: Singh, A.D. and Damato, B., eds. Clinical Ophthalmic Oncology. Berlin: Springer; 2014; p. 123-132
8. Trail, P.A. Antibody directed delivery for treatment of cancer: antibody drug conjugates and immunotoxins. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 3-22
9. Lambert, J.M. Drug-conjugated antibodies for the treatment of cancer. Br. J. Clin. Pharmacol. 76:248-262, 2013
10. Stack, G.D., and Walsh, J.J. Optimising the delivery of tubulin targeting agents through antibody conjugation. Pharm. Res. 29:2972-2984, 2012
11. Perez, H.L., Cardarelli, P.M., Deshpande, S., et al. Antibody-drug conjugates: current status and future directions. Drug Discov. Today. 19:869-881, 2014
12. Dosio, F., Stella, B., Cerioni, S., et al. Advances in anticancer antibody-drug conjugates and immunotoxins. Recent Pat. Anticancer Drug Discov. 9:35-65, 2014
13. Piccaluga, P.P., Martinelli, G., Rondoni, M., et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk. Res. 28:987-990, 2004
14. US Department of Health and Human Services. Common teminology criteria for adverse events (CTCAE), Version 4.0 Bethesda: National Institutes of Health, National Cancer Institute, 2009. evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03- 2010-06-14-QuickReference-5•7.pdf Last accessed August 20, 2015
15. Tolcher, A.W., Ochoa, L., Hammond, L.A., et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21:211-222, 2003
16. Ricart, A.D. Immunoconjugates against solid tumors: mind the gap. Clin. Pharmacol. Ther. 89:513-523, 2011
17. Lutz, R.J., Xie, H., Widdison, W.C., et al. HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. AACR Meeting Abstracts. 334, 2005
18. Mita, M.M., Ricart, A.D., Mita, A.C., et al. A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. J. Clin. Oncol. 25: 3062, 2007
19. Goff, L.W., Papadapoulos, K., Posey, J.A., et al. Abstract: a phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. J. Clin. Oncol. 27:e15625, 2009
20. Pegram, M., and Slamon, D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin. Oncol.27:13-19, 2000
21. Mitri, Z., Constantine, T., and O'Regan, R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother. Res. Pract. 2012:743193, 2012
22. Slamon, D.J., Clark, G.M., Wong, S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177-182, 1987
23. Rugo, H.S., Krop, I.E., and Chu, Y.-W. Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive cancer with a focus on breast cancer. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 179-210
24. Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357:39-51, 2007
25. Phillips, G.D.L., Li, G., Dugger, D.L., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68:9280-9290, 2008
26. Krop, I.E., Beeram, M., Modi, S., et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28:2698-2704, 2010
27. Burris, H.A., Rugo, H.S., Vukelja, S.J., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29:398-405, 2011
28. Beeram, M., Krop, I.E., Burris, H.A., et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 118:5733-5740, 2012
29. Lambert, J.M., Blanc, V., Le Bail, N., et al. Targeting CD19 with SAR3419, an anti-CD19-maytansinoid conjugate for the treatment of B cell malignancies. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 149-160
30. Scheuermann, R., and Racila, E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma. 18:385-397, 1995
31. Lutz, R.J., Zuany-Amorim, C., Vrignaud, P., et al. Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B cell lymphomas. AACR Meeting Abstracts. 47:877, 2006
32. Al-Katib, A.M., Aboukameel, A., Mohammad, R., et al. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin. Cancer. Res. 15:4038-4045, 2009
33. Carol, H., Szymanska, B., Evans, K., et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin. Cancer Res. 19:1795-1805, 2013
34. Blanc, V., Bousseau, A., Caron, A., et al. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res. 17:6448-6458, 2011
35. Younes, A., Kim, S., Romaguera, J., et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J. Clin. Oncol. 30:2776-2782, 2012
36. Coiffier, B., Ribrag, V., Dupuis, J., et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/ refractory B-cell non-Hodgkins lymphoma (NHL). J. Clin. Oncol. 29, 2011. Abstract 8017
37. Ribrag, V., Dupuis, J., Tilly, H., et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 20:213-220, 2014
38. Moskowitz, C.H., Forero-Torres, A., Shah, B.D., et al. Interim analysis of a phase 1 study of the antibody-drug conjugate sgn-cd19a in relapsed or refractory b-lineage non-Hodgkin lymphoma. Blood. 124:1741, 2014
39. Fathi, A.T., Chen, R., Trippett, T.M., et al. Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood. 124:963-963, 2014
40. Hernandez-Caselles, T., Martinez-Esparza, M., Perez-Oliva, A.B., et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J. Leukoc. Biol. 79:46-58, 2006
41. Larson, R., Boogaerts, M., Estey, E., et al. Antibodytargeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 16:1627-1636, 2002
42. Chari, R.J.V., Xie, H., Leece, B.L., et al. Preclinical evaluation of an anti-CD33-maytansinoid immunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia. Am. Assoc. Cancer Res. Abstract-LB-287, 2005
43. Lapusan, S., Vidriales, M.B., Thomas, X., et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest. New Drugs. 30:1121-1131, 2012
44. Polson, A.G., Ho, W.Y., and Ramakrishnan, V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin. Investig. Drugs. 20:75-85, 2011
45. Oflazoglu, E., Stone, I.J., Gordon, K., et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res. 14:6171-6180, 2008
46. Alley, S.C., Zhang, X., Okeley, N.M., et al. The pharmacologic basis for antibody-auristatin conjugate activity. J. Pharmacol. Exp. Ther. 330:932-938, 2009
47. Tannir, N.M., Forero-Torres, A., Ramchandren, R., et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest. New Drugs. 32: 1246-1257, 2014
48. Thompson, J., Forero-Torres, A., Heath, E., et al. The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): a phase I study. ASCO Annual Meeting Proceedings. 29:3071, 2011
49. Carrigan, C., Zuany-Amorim, C., Mayo, M., et al. 525 POSTER preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer. Eur. J. Cancer Suppl. 6:166, 2008
50. Boni, V., Rixe, O., Rasco, D., et al. Abstract A73: a phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870). Mol. Cancer Ther. 12:A73, 2013
51. Hamann, P.R., Hinman, L.M., Beyer, C.F., et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13:40-46, 2002
52. Ravandi, F. Gemtuzumab ozogamicin: one size does not fit all\-The case for personalized therapy. J. Clin. Oncol. 29:349-351, 2011
53. Petersdorf, S., Kopecky, K., Stuart, R.K., et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 114:790, 2009
54. Xiao, Z., Jackson, D., and Tice, D.A. EphA2 immunoconjugate. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 241-253
55. Jackson, D., Gooya, J., Mao, S., et al. A human antibodydrug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 68:9367-9374, 2008
56. Lee, J.-W., Han, H.D., Shahzad, M.M., et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 101:1193-1205, 2009
57. Lee, J.-W., Stone, R.L., Lee, S.J., et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin. Cancer Res. 16:2562-2570, 2010
58. Annunziata, C.M., Kohn, E.C., LoRusso, P., et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest. New Drugs. 31:77-84, 2013
59. Lambert, J.M., O'Leary, J., Whiteman, K.R., et al. Targeting CD56 (NCAM)-expressing neoplasms with lorvotuzumab mertansine. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 273-293
60. Tassone, P., Goldmacher, V.S., Neri, P., et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 104:3688-3696, 2004
61. Tassone, P., Gozzini, A., Goldmacher, V., et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2¢-deacetyl-N2¢-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 64:4629-4636, 2004
62. Lutz, R.J., and Whiteman, K.R. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs. 1: 548-551, 2009
63. Woll, P.J., O'Brien, M., Fossella, F., et al. Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann. Oncol. 21, 2010
64. Wilson, C., Leaning, D., Shankland, K., et al. Cortical blindness as an unusual adverse drug reaction. J. Med. Cases. 1:47-50, 2010
65. Ikeda, H., Hideshima, T., Fulciniti, M., et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15:4028-4037, 2009
66. O'Connell, F.P., Pinkus, J.L., and Pinkus, G.S. CD138 (Syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am. J. Clin. Pathol. 121:254-263, 2004
67. Chanan-Khan, A., Jagannath, S., Heffner, T., et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. Blood. 114:69-73, 2009
68. Moore, K., Ponte, J., LoRusso, P., et al. Relationship of pharmacokinetics (PK), toxicity and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa)-targeting antibody drug conjugate in patients with epithelial ovarian cancer and other FRa-positive solid tumors. J. Clin. Oncol. 32:5571, 2014
69. Timotheadou, E. Emerging targeted agents in endometrial cancer treatment. OA Cancer. 1:9, 2013
70. Moore, K., Martin, L., Seward, S., et al. Preliminary single agent activity of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. J. Clin. Oncol. 33:5518, 2015
71. Beck, A., Lambert, J., Sun, M., et al. Fourth world antibody-drug conjugate summit: February 29-March 1, 2012, Frankfurt, Germany. MAbs. 4:637-647, 2012
72. Thompson, J.A., Motzer, R., Molina, A.M., et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). J. Clin. Oncol. 33:2503, 2015
73. Ratain, M.J., and Plunkett, W.K. Principles of pharmacodynamics. In: Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., et al., eds. Holland-Frei Cancer Medicine. Hamilton, ON: BC Decker; 2003. www.ncbi.nlm.nih.gov/ books/NBK13774/ Last accessed August 15, 2015
74. Rudmann, D.G. On-target and off-target-based toxicologic effects. Toxicol. Pathol. 41:310-314, 2013
75. Burstein, H.J., Manola, J., Younger, J., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol. 18:1212-1219, 2000
76. Al-Tweigeri, T., Nabholtz, J.-M., and Mackey, J.R. Ocular toxicity and cancer chemotherapy: a review. Cancer. 78: 1359-1373, 1996
77. Ibrahim, N.K., Desai, N., Legha, S., et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8:1038-1044, 2002
78. Esmaeli, B., Ahmadi, M.A., Rivera, E., et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch. Ophthal. 120:1180-1182, 2002
79. Esmaeli, B., Hortobagyi, G., Esteva, F., et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann. Oncol. 13:218-221, 2002
80. Goldmacher, V.S., Singh, R., Chittenden, T., et al. Linker technology and impact of linker design on ADC properties. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 117-135
81. Erickson, H., Wilhelm, S., Widdison, W., et al. Evaluation of the cytotoxic potencies of the major maytansinoid metabolites of antibody maytansinoid conjugates detected in vitro and in preclinical mouse models. AACR Meeting Abstracts. 2008:2150, 2008
82. Kovtun, Y.V., Audette, C.A., Ye, Y., et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66:3214-3221, 2006
83. Widdison, W.C., and Chari, R.V. Factors involved in the design of cytotoxic payloads for antibody-drug conjugates. In: Phillips, G.L., ed. Antibody-Drug Conjugates and Immunotoxins. New York: Springer; 2013; p. 93-115
84. Fracht, H.U., Harvey, T.J., and Bennett, T.J. Transient corneal microcysts associated with interferon therapy. Cornea. 24:480-481, 2005
85. Dhillon, V.K., Faraj, L.A., Elalfy, M.S., et al. Corneal microcysts. Br. J. Ophthalmol. 98:138-140, 2014
86. Hopen, G., Mondino, B.J., Johnson, B.L., et al. Corneal toxicity with systemic cytarabine. Am. J. Ophthalmol. 91:500-504, 1981
87. Herzig, R.H., Wolff, S.N., Lazarus, H.M., et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 62:361-369, 1983
88. Gressel, M., and Tomsak, R. Keratitis from high dose intravenous cytarabine. Lancet. 320:273, 1982
89. Guthoff, T., Tietze, B., Meinhardt, B., et al. Cytosinearabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica. 224:308-311, 2009
90. Vaccaro, M., Pollicino, A., Barbuzza, O., et al. Trichomegaly of the eyelashes following treatment with cetuximab. Clin. Exp. Dermatol. 34:402-403, 2009
91. Fraunfelder, F.T., and Fraunfelder, F.W. Trichomegaly and other external eye side effects associated with epidermal growth factor. Cutan. Ocul. Toxicol. 31:195-197, 2012
92. Garibaldi, D.C., and Adler, R.A. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal. Plast. Reconstr. Surg. 23:62-63, 2007
93. Foerster, C.G., Cursiefen, C., and Kruse, F.E. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea. 27:612-614, 2008
94. Basti, S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs. 30:S10-S16, 2007
95. Dranko, S., Kinney, C., and Ramanathan, R.K. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin. Colorectal Cancer. 6:224-225, 2006
96. Mahipal, A., Kothari, N., and Gupta, S. Epidermal growth factor receptor inhibitors: coming of age. Cancer Control. 21:74-79, 2014
97. Schrohl, A.S., Pedersen, H.C., Jensen, S.S., et al. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology. 59:975-983, 2011
98. Knop, E., and Knop, N. Anatomy and immunology of the ocular surface. In: Niederkorn, J.Y. and Kaplan, H.J., eds. Chemical Immunology and Allergy. Basel: Karger; 2007; p. 36-49
99. Smolin, G. Cellular response to inflammation at the limbus. Eye. 3:167-171, 1989
100. Hoyer, J.D., Grogg, K.L., Hanson, C.A., et al. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am. J. Clin. Pathol. 129:316-323, 2008
101. Hamrah, P., and Dana, M.R. Corneal antigen-presenting cells. In: Niederkorn, J.Y. and Kaplan, H.J., eds. Chemical Immunology and Allergy. Basel: Karger; 2007; p. 58-70
102. Han, T.H., and Zhao, B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab. Dispos. 42: 1914-1920, 2014
103. Wang, L., Amphlett, G., Blättler, W.A., et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Prot. Sci. 14:2436-2446, 2005
104. Hamblett, K.J., Senter, P.D., Chace, D.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10: 7063-7070, 2004
105. Strop, P., Liu, S.-H., Dorywalska, M., et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20:161-167, 2013
106. Behrens, C.R., and Liu, B. Methods for site-specific drug conjugation to antibodies. MAbs. 6:46-53, 2013
107. Qin, A., Watermill, J., Mastico, R.A., et al. The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors. J. Clin. Oncol. 26, 2008
108. Jackson, D., and Stover, D. Using the lessons learned from the clinic to improve the preclinical development of antibody drug conjugates. Pharm. Res. 1-12, 2014
109. Siolas, D., and Hannon, G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73:5315-5319, 2013
110. Sausville, E.A., and Burger, A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66:3351-3354, 2006
111. Haddish-Berhane, N., Shah, D.K., Ma, D., et al. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J. Pharmacokinet. Pharmacodyn. 40:557-571, 2013
112. Sassoon, I., and Blanc, V. Antibody-drug conjugate (ADC) clinical pipeline: a review.'' Methods Mol. Biol. 1045:1-27, 2013